Macroaxis: Personalized Investing
Personalized Investing and
Digital Wealth Optimization

IDXX NEOG ABAX VIVO Utilities Small Value Electronics Precious Metals 
Benchmark SP 500  1,629   22.88  Index Moved Down -1.39% United States ...


Processing
Collecting data for VIVO

Meridian quote and profile

 
 Companies |  Insiders  | Dashboard  
     
21.45
  
STOCK
(0.27)  Macroaxis: -1.24 Down   1.24%  
Year To Date
16.1923.05
Last 1 Month(s)
21.1122.02
Trading Day 
21.4221.74
June 19 2013 

Diversification Suggestion

Use Meridian to protect against small markets fluctuations. The stock experiences somewhat bearish sentiment, but market may correct it shortly
Analyze Meridian Bioscience Trend or Check current 30 days Meridian correlation with market (S&P 500)
1 Month Beta 0.73  
Highest Price:  
Lowest Price:  
22.02  
21.11  
May 28 2013 
June 05 2013 
As returns on market increase, Meridian returns are expected to increase less than the market. However during bear market, the loss on holding Meridian will be expected to be smaller as well.
Meridian Bioscience Inc Small BetaMeridian Bioscience Beta Legend
VIVO United States Nasdaq
Meridian Bioscience Inc
Healthcare
Diagnostic Substances
Benchmark S&P 500
http://www.meridianbioscience.com
Contact Number: 513. 271. 3700
Currency: USD - US Dollar
Traded on NASDAQ
    
Current Valuation874.1 M
Shares Outstanding41.47 M
Number of Shares Shorted6.51 M
Revenue178.84 M
 thisRed VIVO VIVO agains markets  1.24 % Macroaxis: change 1.24 Moved Down  
 
 United States Russel   1.35 % Macroaxis: change 1.35 Moved Down  
 
 United States SP 500   1.39 % Macroaxis: change 1.39 Moved Down  
 
 United States NYSE   1.53 % Macroaxis: change 1.53 Moved Down  
 
Compare to Competition Alpha & Beta   Get Advice

Meridian Leadership

John Kraeutler CEO and Director
William Motto Founder and Executive Chairman
Marviette Johnson Vice President - Human Resources
Marco Calzavara President of Meridian Bioscience Europe and Managing Director of Meridian Bioscience Europe

Meridian Price and Market Media

The median price of Meridian for the period between Mon, May 20, 2013 and Wed, Jun 19, 2013 is 21.71 with a coefficient of variation of 1.15. The daily time series for the period is distributed with a sample standard deviation of 0.25, arithmetic mean of 21.65, and mean deviation of 0.2. The Stock received substential amount of media coverage during this period.
Meridian         SP 500
Price Growth (%)
 
Change Benchmark  Embed  Export  Timeline
1
VIVO January 2014 Options Begin Trading05/21/2013Macroaxis: Forbes News
2
Hedge Funds Are Crazy About Synta Pharmaceuticals Corp.06/07/2013Macroaxis: News
3
Meridian Bioscience Receives FDA Clearance for New Molecular...06/12/2013Macroaxis: News
4
Meridian Bioscience Inc. Enters into Product Development and...06/14/2013Businesswire News

Meridian Summary

Meridian Bioscience Inc [VIVO] is traded on NASDAQ in USA. It is located in Meridian Bioscience, Inc.Cincinnati, OH and employs 510 people. The company currently falls under 'Small-Cap' category with current market capitalization of 900.25 M. Meridian Bioscience Inc conducts business under Healthcare sector and is part of Diagnostic Substances industry. This company has 41.47 M outstanding shares of which 6.51 M shares are at this time shorted by private and institutional investors with about 36.0 trading days to cover.
Meridian Bioscience, Inc., a life science company, develops, manufactures, sells, and distributes clinical diagnostic test kits primarily for gastrointestinal, viral, respiratory, and parasitic infectious diseases. more
Past Market
Over 30
Days
0
Out Of
100
 
Chance of
Less
Than
45 %
 
Follow Meridian with Macroaxis syndicated feed, custom widget, or your favorite custom stock ticker
Add To Reader
 
Add Meridian to your reader
 

Meridian Research Report

Meridian vs. IDEXX

Correlation analysis and fundamentals comparison between Meridian Bioscience and IDEXX Laboratories

Meridian Executives

Melissa Lueke CFO, Principal Accounting Officer, Executive VP and Secretary

Meridian Directors

Robert Ready Independent Director
James Anderson Independent Director
David Phillips Independent Director

Meridian Fundamentals

Price to Book vs Net Income
Cash and Equivalents vs Current Asset
Price to Book vs Short Ratio
Gross Profit vs Current Asset

Meridian vs Competition

Meridian vs. IDEXX Laboratories Inc
Meridian vs. Abaxis Inc
Meridian vs. Synta Pharmaceuticals Corp

Meridian June 19 2013 Opportunity Range

Downside Deviation1.17
Information Ratio0.0145
Maximum Drawdown4.08
Value At Risk(1.00)
Potential Upside1.06

 
Analytics
Risk Adjusted Returns Landscape
Live Efficient Frontier
Market Correlation Analysis
Watchlist Analysis
Financial Content
Portfolio Estimation and Projections
Portfolio Theme Builder
 
 
Research Modules
Equities Backtesting Analysis
Instant Retirement Optimizer
Cross-portfolio RSS and Mobile Access
Company, fund, and ETF Directory
Financial Advisor Directory
Insider and Manager Directory
Wealth Management
 Gadgets, Widgets, and Apps          
  
 
Services And Technology
Frequently Asked Questions
Quick Product Tour
Product Technology Overview
Solution Methodology
Plans and Pricing
 
Free Investor Tools
World Market Correlations
Instant Equity Comparator
Watchlist Analysis
Position Suggestions
Equity Alpha Analysis
 
About Us
About Macroaxis
Contact Us
Product Terms Of Use
Service Privacy Policy
Advertising Opportunities
Content

Thanks for checking out Macroaxis

Tell us what you like and what you don't like. We promise we'll not only listen but write you back

Contact Us
Macroaxis is user-driven community of investors. We appreciate any feedback or comment you can provide. Please fill out our quick survey to help us provide your with a better service and user experience

Fill Out Quick Survey
Most of the functionality on our site is free to use. However we do provide premium service to sophisticated investors. Our premium subscription will give you unprecedented capabilities to optimize your portfolios using robust financial analysis toolkit, fast mean-variance optimization engine, and proven portfolio theory

Go Premium